The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders.
The global Rufinamide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Rufinamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Rufinamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Rufinamide in Adults is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Rufinamide include Eisai, Glenmark Pharms, Mylan and West-ward Pharms, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Rufinamide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rufinamide.
Report Scope
The Rufinamide market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rufinamide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rufinamide companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eisai
Glenmark Pharms
Mylan
West-ward Pharms
Segment by Type
Tablets
Oral suspension
Segment by Application
Adults
Pediatric patients
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rufinamide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders.
The global Rufinamide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Rufinamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Rufinamide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Rufinamide in Adults is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Rufinamide include Eisai, Glenmark Pharms, Mylan and West-ward Pharms, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Rufinamide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rufinamide.
Report Scope
The Rufinamide market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rufinamide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rufinamide companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eisai
Glenmark Pharms
Mylan
West-ward Pharms
Segment by Type
Tablets
Oral suspension
Segment by Application
Adults
Pediatric patients
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rufinamide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rufinamide Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablets
1.2.3 Oral suspension
1.3 Market by Application
1.3.1 Global Rufinamide Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Adults
1.3.3 Pediatric patients
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rufinamide Market Perspective (2019-2030)
2.2 Rufinamide Growth Trends by Region
2.2.1 Global Rufinamide Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Rufinamide Historic Market Size by Region (2019-2024)
2.2.3 Rufinamide Forecasted Market Size by Region (2025-2030)
2.3 Rufinamide Market Dynamics
2.3.1 Rufinamide Industry Trends
2.3.2 Rufinamide Market Drivers
2.3.3 Rufinamide Market Challenges
2.3.4 Rufinamide Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rufinamide Players by Revenue
3.1.1 Global Top Rufinamide Players by Revenue (2019-2024)
3.1.2 Global Rufinamide Revenue Market Share by Players (2019-2024)
3.2 Global Rufinamide Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rufinamide Revenue
3.4 Global Rufinamide Market Concentration Ratio
3.4.1 Global Rufinamide Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rufinamide Revenue in 2023
3.5 Rufinamide Key Players Head office and Area Served
3.6 Key Players Rufinamide Product Solution and Service
3.7 Date of Enter into Rufinamide Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Rufinamide Breakdown Data by Type
4.1 Global Rufinamide Historic Market Size by Type (2019-2024)
4.2 Global Rufinamide Forecasted Market Size by Type (2025-2030)
5 Rufinamide Breakdown Data by Application
5.1 Global Rufinamide Historic Market Size by Application (2019-2024)
5.2 Global Rufinamide Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Rufinamide Market Size (2019-2030)
6.2 North America Rufinamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Rufinamide Market Size by Country (2019-2024)
6.4 North America Rufinamide Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rufinamide Market Size (2019-2030)
7.2 Europe Rufinamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Rufinamide Market Size by Country (2019-2024)
7.4 Europe Rufinamide Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rufinamide Market Size (2019-2030)
8.2 Asia-Pacific Rufinamide Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Rufinamide Market Size by Region (2019-2024)
8.4 Asia-Pacific Rufinamide Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rufinamide Market Size (2019-2030)
9.2 Latin America Rufinamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Rufinamide Market Size by Country (2019-2024)
9.4 Latin America Rufinamide Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rufinamide Market Size (2019-2030)
10.2 Middle East & Africa Rufinamide Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Rufinamide Market Size by Country (2019-2024)
10.4 Middle East & Africa Rufinamide Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eisai
11.1.1 Eisai Company Detail
11.1.2 Eisai Business Overview
11.1.3 Eisai Rufinamide Introduction
11.1.4 Eisai Revenue in Rufinamide Business (2019-2024)
11.1.5 Eisai Recent Development
11.2 Glenmark Pharms
11.2.1 Glenmark Pharms Company Detail
11.2.2 Glenmark Pharms Business Overview
11.2.3 Glenmark Pharms Rufinamide Introduction
11.2.4 Glenmark Pharms Revenue in Rufinamide Business (2019-2024)
11.2.5 Glenmark Pharms Recent Development
11.3 Mylan
11.3.1 Mylan Company Detail
11.3.2 Mylan Business Overview
11.3.3 Mylan Rufinamide Introduction
11.3.4 Mylan Revenue in Rufinamide Business (2019-2024)
11.3.5 Mylan Recent Development
11.4 West-ward Pharms
11.4.1 West-ward Pharms Company Detail
11.4.2 West-ward Pharms Business Overview
11.4.3 West-ward Pharms Rufinamide Introduction
11.4.4 West-ward Pharms Revenue in Rufinamide Business (2019-2024)
11.4.5 West-ward Pharms Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Rufinamide Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tablets
Table 3. Key Players of Oral suspension
Table 4. Global Rufinamide Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Rufinamide Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Rufinamide Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Rufinamide Market Share by Region (2019-2024)
Table 8. Global Rufinamide Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Rufinamide Market Share by Region (2025-2030)
Table 10. Rufinamide Market Trends
Table 11. Rufinamide Market Drivers
Table 12. Rufinamide Market Challenges
Table 13. Rufinamide Market Restraints
Table 14. Global Rufinamide Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Rufinamide Market Share by Players (2019-2024)
Table 16. Global Top Rufinamide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rufinamide as of 2023)
Table 17. Ranking of Global Top Rufinamide Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Rufinamide Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Rufinamide Product Solution and Service
Table 21. Date of Enter into Rufinamide Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Rufinamide Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Rufinamide Revenue Market Share by Type (2019-2024)
Table 25. Global Rufinamide Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Rufinamide Revenue Market Share by Type (2025-2030)
Table 27. Global Rufinamide Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Rufinamide Revenue Market Share by Application (2019-2024)
Table 29. Global Rufinamide Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Rufinamide Revenue Market Share by Application (2025-2030)
Table 31. North America Rufinamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Rufinamide Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Rufinamide Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Rufinamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Rufinamide Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Rufinamide Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Rufinamide Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Rufinamide Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Rufinamide Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Rufinamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Rufinamide Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Rufinamide Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Rufinamide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Rufinamide Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Rufinamide Market Size by Country (2025-2030) & (US$ Million)
Table 46. Eisai Company Detail
Table 47. Eisai Business Overview
Table 48. Eisai Rufinamide Product
Table 49. Eisai Revenue in Rufinamide Business (2019-2024) & (US$ Million)
Table 50. Eisai Recent Development
Table 51. Glenmark Pharms Company Detail
Table 52. Glenmark Pharms Business Overview
Table 53. Glenmark Pharms Rufinamide Product
Table 54. Glenmark Pharms Revenue in Rufinamide Business (2019-2024) & (US$ Million)
Table 55. Glenmark Pharms Recent Development
Table 56. Mylan Company Detail
Table 57. Mylan Business Overview
Table 58. Mylan Rufinamide Product
Table 59. Mylan Revenue in Rufinamide Business (2019-2024) & (US$ Million)
Table 60. Mylan Recent Development
Table 61. West-ward Pharms Company Detail
Table 62. West-ward Pharms Business Overview
Table 63. West-ward Pharms Rufinamide Product
Table 64. West-ward Pharms Revenue in Rufinamide Business (2019-2024) & (US$ Million)
Table 65. West-ward Pharms Recent Development
Table 66. Research Programs/Design for This Report
Table 67. Key Data Information from Secondary Sources
Table 68. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Rufinamide Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Rufinamide Market Share by Type: 2023 VS 2030
Figure 3. Tablets Features
Figure 4. Oral suspension Features
Figure 5. Global Rufinamide Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Rufinamide Market Share by Application: 2023 VS 2030
Figure 7. Adults Case Studies
Figure 8. Pediatric patients Case Studies
Figure 9. Rufinamide Report Years Considered
Figure 10. Global Rufinamide Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Rufinamide Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Rufinamide Market Share by Region: 2023 VS 2030
Figure 13. Global Rufinamide Market Share by Players in 2023
Figure 14. Global Top Rufinamide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rufinamide as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Rufinamide Revenue in 2023
Figure 16. North America Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Rufinamide Market Share by Country (2019-2030)
Figure 18. United States Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Rufinamide Market Share by Country (2019-2030)
Figure 22. Germany Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Rufinamide Market Share by Region (2019-2030)
Figure 30. China Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Rufinamide Market Share by Country (2019-2030)
Figure 38. Mexico Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Rufinamide Market Share by Country (2019-2030)
Figure 42. Turkey Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Rufinamide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Eisai Revenue Growth Rate in Rufinamide Business (2019-2024)
Figure 45. Glenmark Pharms Revenue Growth Rate in Rufinamide Business (2019-2024)
Figure 46. Mylan Revenue Growth Rate in Rufinamide Business (2019-2024)
Figure 47. West-ward Pharms Revenue Growth Rate in Rufinamide Business (2019-2024)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
